A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04968574
• Other study ID #: ENV-IPF-101
• Status: Completed
• Phase: Phase 2
• Start date: August 26, 2021
• Est. completion date: November 30, 2023

Study information

• Verified date: February 2024
• Source: Endeavor Biomedicines, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• IPF diagnosis based upon American Thoracic Association, Japanese Respiratory Society, European Respiratory Society, Latin American Thoracic Association guidelines within the last 7 years. Diagnosis will be confirmed to be consistent with IPF by centrally read high resolution computed tomography (HRCT).

• Ability to successfully perform lung function tests.

• Subjects are willing to remain on study treatment for the duration of the study.

• Subjects have a full understanding of the informed consent.

Exclusion Criteria:

• Evidence of other known causes of interstitial lung disease (ILD) (e.g., domestic, and occupational environmental exposures, connective tissue disease [CTD], and drug toxicity), lung transplant expected within 12 months of screening or evidence of clinically significant lung disease other than IPF including but not limited to asthma, chronic obstructive pulmonary disease (COPD), uncontrolled pulmonary hypertension and emphysema where computed tomography (CT)-assessed extent of emphysema is greater than extent of fibrosis.

• History of malignancy, including carcinoma during the preceding 5 years. With the following exceptions:

1. Prior history of in situ basal or squamous cell skin cancer that was successfully treated with curative therapies.

2. Subjects with other malignancies if they have been continuously disease free for at least 5 years prior to study start.

3. Subjects with prostate cancer that are managed by surveillance are also eligible.

• Current use of supplemental oxygen for any condition unless prior approval is received from the Sponsor.

• Smoking within 6 months of study start, current smoker, or unwillingness to refrain from smoking during the clinical trial duration.

• Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).

• Occurrence of serious illness requiring hospitalization within 90 days prior to study start.

• Current or previous use (within 30 days prior to study start) of the following:

1. N-acetylcysteine

2. endothelin receptor antagonist

3. riociguat

4. prostacyclin or prostacyclin analogue

5. Warfarin for IPF

6. Cytotoxic agents (e.g., colchicine if used for IPF)

7. Radiation to the lungs

8. Pulmonary rehabilitation

9. Investigational agent for IPF

10. Immunosuppressive medications (e.g., methotrexate, azathioprine)

11. Systemic or inhaled glucocorticosteroids

12. Antifibrotic therapy (e.g., nintedanib, pirfenidone)

• Regular use of phosphodiesterase type-5 inhibitor, occasional use for erectile dysfunction will be allowed.

• Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start.

• Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose.

• Females that are pregnant or nursing.

• Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose.

• Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose.

• Subjects with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.

• Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• taladegib
hedgehog pathway inhibitor dosed once daily
• placebo
identical tablets to the experimental arm with no active ingredient

Locations

Country	Name	City	State
Australia	Research Site	Benowa	Queensland
Australia	Research Site	Box Hill	Victoria
Australia	Research Site	Clayton	Victoria
Australia	Research Site	Liverpool	New South Wales
Canada	Research Site	Sherbrooke	Quebec
Canada	Research Site	Vancouver	British Columbia
Korea, Republic of	Research Site (Namdong District)	Incheon
Korea, Republic of	Research Site (Bundang District)	Seongnam
Korea, Republic of	Research Site (Gangnam District)	Seoul
Korea, Republic of	Research Site (Seongbuk District)	Seoul
Korea, Republic of	Research Site (Songpa District)	Seoul
Malaysia	Research Site	Batu Caves
Malaysia	Research Site	Kota Bharu
Malaysia	Research Sire	Kuala Lumpur
Malaysia	Research Site	Kuala Lumpur
Malaysia	Research Site	Kuala Lumpur
Mexico	Research Site	Chihuahua
Mexico	Research Site	Mexico City
Mexico	Research Site	Mexico City
Mexico	Research Site	Monterrey	Nuevo Leon
Mexico	Research Site	Monterrey	Nuevo Leon
Mexico	Research Site	Oaxaca
Mexico	Research Site	Puebla
Mexico	Research Site	San Nicolás De Los Garza	Nuevo Leon

Sponsors (1)

Lead Sponsor	Collaborator
Endeavor Biomedicines, Inc.

Countries where clinical trial is conducted

Australia,  Canada,  Korea, Republic of,  Malaysia,  Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change from baseline of FVC		Baseline and Week 6
Other	Change from baseline of FVC		Baseline and Week 18
Other	Change from baseline of DLCO		Baseline and Week 6
Other	Change from baseline of DLCO		Baseline and Week 18
Other	Change from baseline of patient reported outcomes by the UCSD SOBQ		Baseline and Week 6
Other	Change from baseline of patient reported outcomes by the UCSD SOBQ		Baseline and Week 18
Primary	Change from baseline in frequency of adverse events (AEs)	An AE is any untoward medical occurrence in a study subject administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment under investigation. Frequency of a given AE is determined by dividing the total number of that AE observed during the study by the total number of subjects in the study.	Baseline to Week 18
Primary	Change from baseline in severity of AEs	Severity of AEs are categorized as mild, moderate or severe as described below: Mild - Events require minimal or no treatment and do not interfere with the subject's daily activities.; Moderate - Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some interference with functioning.; Severe - Events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually potentially life-threatening or incapacitating.	Baseline to Week 18
Primary	Change from baseline in vital sign measurements - pulse	Comparison of a subject's pulse rate at the beginning of the study to that subject's pulse rate at the completion of the study.	Baseline to Week 18
Primary	Change from baseline in vital sign measurements - blood pressure	Comparison of a subject's blood pressure at the beginning of the study to that subject's blood pressure at the completion of the study.	Baseline to Week 18
Primary	Change from baseline in vital sign measurements - respiration rate	Comparison of a subject's respiration rate (number of breaths taken per minute while at rest) at the beginning of the study to that subject's respiration rate at the completion of the study.	Baseline to Week 18
Primary	Change from baseline in vital sign measurements - temperature	Comparison of a subject's body temperature at the beginning of the study to that subject's body temperature at the completion of the study.	Baseline to Week 18
Primary	Change from baseline in blood oxygen saturation level	Comparison of a subject's blood oxygen saturation level (measured at rest using a pulse oximeter) at the beginning of the study to that subject's blood oxygen saturation level at the completion of the study.	Baseline to Week 18
Primary	Incidence of clinical laboratory abnormalities	Assessment of the clinical laboratory measurements (chemistry, hematology, urinalysis parameters) that are above or below the laboratory normal ranges. Incidence of clinical laboratory abnormalities is determined by dividing the total number of clinical laboratory abnormalities by the total number of subjects in the study.	Baseline to Week 18
Primary	Severity of clinical laboratory abnormalities	Assessment of the severity (defined as either clinically significant or not clinically significant) for the clinical laboratory abnormalities observed during the study.	Baseline to Week 18
Primary	Number of hospitalizations	Assessment of the number of hospitalizations for any reason observed among all subjects from the beginning of the study to the completion of the study.	Baseline to Week 18
Secondary	Change from baseline of FVC (forced vital capacity)	FVC is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured during a spirometry test.	Baseline and Week 12
Secondary	Change from baseline of DLCO (diffusing capacity of the lungs for carbon monoxide)	DLCO is a measurement of the ease of transfer for carbon monoxide molecules from alveolar gas to the hemoglobin of the red blood cells in the pulmonary circulation.	Baseline and Week 12
Secondary	Change from baseline of patient reported outcomes by the University of California-San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)	The UCSD SOBQ consists of 24 questions (21 assess severity of shortness of breath during specific activities of daily living; 3 additional items ask about limitations due to: shortness of breath, fear of harm from overexertion and fear of shortness of breath). Each question has a 6-point scale (0 = "not at all" to 5 = "maximal or unable to do because of breathlessness"), resulting in a total score ranging from 0 to 120 (a higher score represents a worse outcome).	Baseline and Week 12